In a report released yesterday, Faisal Khurshid from Leerink Partners reiterated a Buy rating on Zura Bio. The company’s shares closed yesterday at $1.96. Elevate Your Investing ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic ...

Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in ...

Spyre Therapeutics is a biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody ...

Spyre Therapeutics is a biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody ...